Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Advanced Accelerator Applications has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units.
LIPPERT, JOHN WILLIAM is the busiest examiner with 1 busiest examiner pending action. The 2 pending actions are divided equally between the 2 distinct examiners assigned to the company's applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 1 | 59.7% | +39.4% |
| MOSHER, ERIC PARKER | 1 | 75.0% | +75.0% |
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17579909 | Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors | JONES, DAMERON LEVEST | 12d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17579909 | Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors | JONES, DAMERON LEVEST | 12d |
| 18708825 | COMBINATION THERAPY FOR TREATING LUNG CANCER | LIPPERT, JOHN WILLIAM | — |
| 18704804 | COMBINATION THERAPY OF RADIONUCLIDE COMPLEX | MOSHER, ERIC PARKER | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1612 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18708825 | COMBINATION THERAPY FOR TREATING LUNG CANCER | LIPPERT, JOHN WILLIAM | 1615 | §103§112DP | Non-Final OA | — | Pending | May 09, 2024 |
| 18704804 | COMBINATION THERAPY OF RADIONUCLIDE COMPLEX | MOSHER, ERIC PARKER | 1612 | §102§103§112DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 17579909 | Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors | JONES, DAMERON LEVEST | 1618 | §103§112 | Final Rejection | 12d | Pending | Jan 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAdvanced Accelerator Applications has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
John William Lippert has the most, with 1 of Advanced Accelerator Applications's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.